Placebo | Baricitinib 4-mg | |||||
---|---|---|---|---|---|---|
Total Pts | Pts (%) with Overall Infection | Pts (%) with Serious Infection | Total Pts | Pts (%) with Overall Infection | Pts (%) with Serious Infection | |
Neutropenia CTCAE Grade | ||||||
0 (≥2x109 cells/L) | 985 | 279 (28.3) | 16 (1.6) | 853 | 313 (36.7) | 13 (1.5) |
1 (<2 and ≥1.5x109 cells/L) | 34 | 10 (29.4) | 0 | 74 | 32 (43.2) | 1 (1.4) |
2 (<1.5 and ≥1.0x109 cells/L) | 9 | 0 | 0 | 27 | 11 (40.7) | 0 |
3 (<1.0 and ≥0.5x109 cells/L) | 1 | 1 (100.0)1 | 0 | 3 | 1 (33.3)2 | 0 |
4 (<0.5x109 cells/L) | 0 | 0 | 0 | 0 | 0 | 0 |
Lymphopenia CTCAE Grade | ||||||
0 (≥1.1x109cells/L) | 710 | 201 (28.3) | 12 (1.7) | 704 | 246 (34.9) | 8 (1.1) |
1 (<1.1 and ≥0.8x109 cells/L) | 233 | 65 (27.9) | 2 (0.9) | 205 | 81 (39.5) | 2 (1.0) |
2 (<0.8 and ≥0.5x109 cells/L) | 103 | 30 (29.1) | 1 (1.0) | 71 | 31 (43.7) | 3 (4.2) |
3 (<0.5 and ≥0.2x109 cells/L) | 13 | 3 (23.1) | 1 (7.7) | 8 | 4 (50.0) | 1 (12.5) |
4 (<0.2x109 cells/L) | 0 | 0 | 0 | 0 | 0 | 0 |
CTCAE=common terminology criteria for adverse events; pts = patients. 1Upper respiratory tract; 2Pharyngitis.